What antipsychotic is preferred for an 80‑year‑old man with depression and psychosis on mirtazapine 30 mg, who developed extrapyramidal symptoms with olanzapine 5 mg and worsened when aripiprazole (Abilify) was increased from 5 mg to 10 mg?

Quetiapine is the preferred antipsychotic for this 80-year-old patient with depression and psychosis

Given this patient's history of EPS with olanzapine and clinical worsening with higher-dose aripiprazole, quetiapine at 50-150 mg/day represents the optimal choice, combining low EPS risk with efficacy in geriatric psychotic depression 1.

Clinical Reasoning

Why Quetiapine is Preferred

This patient has demonstrated intolerance to two antipsychotics already:

• Olanzapine 5 mg caused EPS (unusual for olanzapine, suggesting high sensitivity to motor side effects)
• Aripiprazole showed dose-dependent deterioration (initial response at 5 mg, but worsened at 10 mg)

Expert consensus specifically identifies quetiapine as the first-line agent for patients with Parkinson's disease 1, which reflects its exceptionally low propensity for EPS—the most critical consideration for this patient. For agitated dementia with delusions in elderly patients, quetiapine (50-150 mg/day) ranks as a high second-line option alongside risperidone and olanzapine 1.

Critical Safety Considerations in This 80-Year-Old

The 2019 AGS Beers Criteria emphasizes that all antipsychotics carry increased mortality risk in elderly patients with dementia-related psychosis 2. The FDA black box warning for Abilify explicitly states this risk 3. However, when antipsychotics are clinically necessary for psychosis (as in this case), the choice must minimize additional harms.

Quetiapine offers specific advantages:

• Lowest EPS risk among available options
• Better tolerated in patients with movement disorder sensitivity
• Effective for psychotic depression when combined with antidepressants 1

Why Not Return to Lower-Dose Aripiprazole?

While the patient initially responded to aripiprazole 5 mg, the clinical deterioration at 10 mg suggests either:

• Dose-related adverse effects (akathisia, agitation from partial agonism)
• Inadequate efficacy at the lower dose that became apparent over time

The partial D2 agonist mechanism of aripiprazole can paradoxically worsen symptoms in some elderly patients, particularly at higher doses 4. Given the family's clear observation of regression, continuing aripiprazole—even at 5 mg—risks inadequate symptom control.

Dosing Strategy for Quetiapine

Start quetiapine at 25 mg at bedtime, titrate by 25-50 mg every 2-3 days to target 50-150 mg/day 1. This low-and-slow approach minimizes:

• Orthostatic hypotension (major fall risk in 80-year-olds)
• Excessive sedation
• Metabolic effects

Monitoring Requirements

Given this patient's age and medication history:

• Weekly assessment for first month: orthostatic vital signs, sedation, falls
• Metabolic monitoring: baseline and 3-month glucose, lipids (quetiapine has metabolic risk, though less than olanzapine)
• EPS assessment: though unlikely with quetiapine, this patient has proven sensitivity
• QTc monitoring: quetiapine can prolong QTc; obtain baseline and follow-up ECG if risk factors present

The Mirtazapine Interaction

The patient's current mirtazapine 30 mg is appropriate and should be continued. Mirtazapine combined with antipsychotics shows efficacy in elderly psychotic depression 5. Interestingly, mirtazapine may even help mitigate akathisia if it emerges 6, providing additional protection given this patient's EPS history.

No significant pharmacokinetic interaction exists between quetiapine and mirtazapine, though additive sedation and metabolic effects require monitoring 1.

Alternative if Quetiapine Fails

If quetiapine proves ineffective or poorly tolerated, risperidone 0.5-1.0 mg/day would be the next choice 1. While risperidone carries higher EPS risk than quetiapine, it remains lower than olanzapine at equivalent doses and has robust efficacy data in geriatric psychotic depression. Start at 0.25 mg and titrate slowly.

Duration of Treatment

For psychotic depression in elderly patients, expert consensus recommends continuing the antipsychotic for 6 months after remission, then attempting gradual taper while maintaining the antidepressant 1. However, if psychosis recurs during taper, longer-term maintenance at the lowest effective dose is appropriate.

What to Avoid

Based on the AGS Beers Criteria 2 and this patient's history:

• Avoid clozapine: excessive monitoring burden, anticholinergic effects, metabolic risks outweigh benefits
• Avoid typical antipsychotics: unacceptably high EPS risk given this patient's demonstrated sensitivity
• Avoid olanzapine rechallenge: already caused EPS
• Avoid high-dose strategies: this patient deteriorated with dose escalation